Cabozantinib (thyroid cancer) – Addendum to Commission A22-59

Report documents

1. Addendum

   Cabozantinib (thyroid cancer) – Addendum to Commission A22-59

   published on

   15.12.2022

   Document type

   PDF document, 281 kB, DE, not accessible

   Download file : Addendum (PDF document, 281 kB, DE, not accessible)

Additional information

Project details

Project no.

G22-36

Commission

Commission awarded on 11.10.2022 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Health Economics

Topic

Cancer

Note

If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.

Connected Projects

1. Dossier assessment

   Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V

   Project no.

   A22-59

   Last updated

   15.12.2022

   Status: Commission completed